1. TransMedics will present at major healthcare conferences in September. 2. Fireside chat at Morgan Stanley Conference scheduled for September 8. 3. Presentation at Baird Healthcare Conference set for September 9. 4. TransMedics focuses on organ transplant technology for heart, lung, liver.
Participation in prominent investor conferences can attract investor interest, potentially driving stock prices up, similar to past investor presentations that have resulted in positive stock performance for companies in the healthcare sector.
The article discusses upcoming presentations aimed at investors that are crucial for stock performance, highlighting the company's leadership in a vital sector, which can lead to increased visibility and investment.
Investor sentiment often reacts quickly to conference presentations, influencing stock prices immediately following these events.
ANDOVER, Mass., Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on Monday, September 8, 2025, at 10:00 a.m. EST and present at the Baird 2025 Global Healthcare Conference in New York on Tuesday, September 9, 2025, at 12:15 p.m. EST.
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Monday, September 8, 2025
Time: 10:00 a.m. EST
Event: Baird 2025 Global Healthcare Conference
Date: Tuesday, September 9, 2025
Time: 12:15 p.m. EST
A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-upcoming-september-investor-conferences-302537760.html
SOURCE TransMedics Group, Inc.